


EXHIBIT A

MINUTES OF A MEETING OF THE
BOARD OF DIRECTORS OF
ABBOTT LABORATORIES
SEPTEMBER 16-19, 2024


A meeting of the Board of Directors of Abbott Laboratories was held on September 16, 17, 18, and 19, 2024 in Minneapolis, Minnesota, with the meeting held at The Four Seasons Hotel. The meeting commenced at 1:00 p.m. on September 16, 8:00 a.m. on September 17, 7:30 a.m. on September 18, and 8:00 a.m. on September 19. The following Directors were present:

Dr. Robert J. Alpern
Ms. Claire Babineaux-Fontenot
Dr. Sally E. Blount
Mr. Robert B. Ford
Ms. Paola Gonzalez
Ms. Michelle A. Kumbier
Gen. Darren W. McDew
Ms. Nancy McKinstry
Mr. Michael G. O'Grady
Mr. Michael F. Roman
Mr. Daniel J. Starks
Mr. John G. Stratton


constituting a quorum.




Mr. Ford presided and Mr. Allen acted as Secretary of the meeting.




Minutes of a Meeting of the Board of Directors
of Abbott Laboratories
September 16-19, 2024
Page 2




Minutes of a Meeting of the Board of Directors
of Abbott Laboratories
September 16-19, 2024
Page 3




Minutes of a Meeting of the Board of Directors
of Abbott Laboratories
September 16-19, 2024
Page 4




Minutes of a Meeting of the Board of Directors
of Abbott Laboratories
September 16-19, 2024
Page 5




Minutes of a Meeting of the Board of Directors
of Abbott Laboratories
September 16-19, 2024
Page 6




Minutes of a Meeting of the Board of Directors
of Abbott Laboratories
September 16-19, 2024
Page 7




Minutes of a Meeting of the Board of Directors
of Abbott Laboratories
September 16-19, 2024
Page 8



The meeting reconvened on Thursday, September 19, 2024 at 8:00 a.m.,



Minutes of a Meeting of the Board of Directors
of Abbott Laboratories
September 16-19, 2024
Page 9



Minutes of a Meeting of the Board of Directors
of Abbott Laboratories
September 16-19, 2024
Page 10

[REDACTED]

[REDACTED]

[REDACTED]

Minutes of a Meeting of the Board of Directors
of Abbott Laboratories
September 16-19, 2024
Page 11

Mr. Allen began by providing an update on the shareholder derivative lawsuit relating to the voluntary recall in February 2022 of certain powder infant formula products manufactured at Abbott's Sturgis, Michigan manufacturing site, noting that two claims survived a motion to dismiss, which will result in the commencement of discovery, and explaining the grounds for Abbott's motion for reconsideration. Mr. Allen then discussed the option to establish a Special Litigation Committee and related processes. Following discussion, upon motion duly made and seconded, the following resolution was thereupon unanimously adopted:

WHEREAS, Abbott Laboratories (the "Company") and certain current and former directors and officers of the Company are parties to a derivative action titled In re Abbott Laboratories Infant Formula Shareholder Derivative Litigation, No. 22-5513 (N.D. Ill.) (referred to as the "Litigation");

WHEREAS, the claims asserted in the Litigation are assets of the Company;

WHEREAS, the Board of Directors of the Company (the "Board") has determined that it is in the best interests of the Company and its shareholders to form a Special Litigation Committee of the Board ("Special Litigation Committee") to investigate and evaluate the claims asserted in the Litigation and to make a determination as to how the Company should proceed with respect to the Litigation and the claims asserted therein;

WHEREAS, the Board has determined that it is advisable and in the best interests of the Company and its shareholders that a Special Litigation Committee, consisting of Michael O'Grady, shall investigate the claims and allegations in the Litigation and evaluate whether the Company should pursue either of the claims asserted in the Litigation, as well as prepare such reports, arrive at such decisions, and take such other actions in connection with the Litigation as the Special Litigation Committee in its discretion deems appropriate and in the best interests of the Company and its stockholders, in accordance with Illinois law; and

WHEREAS, the Board is satisfied and has determined that Mr. O'Grady is in all respects independent and disinterested with respect to the Litigation;

NOW, THEREFORE, BE IT RESOLVED, that a Special Litigation Committee of the Board be, and it hereby is, created, which Special Litigation Committee shall consist of Michael O'Grady; and

Minutes of a Meeting of the Board of Directors
of Abbott Laboratories
September 16-19, 2024
Page 12

RESOLVED FURTHER, that the Special Litigation Committee be, and hereby is, authorized, empowered, charged, and directed to investigate and evaluate the claims asserted in the Litigation, and to prepare such reports, arrive at such decisions, and take such other actions in connection with the Litigation as the Special Litigation Committee deems appropriate and in the best interests of the Company and its shareholders, in accordance with Illinois law; and

RESOLVED FURTHER, that the Special Litigation Committee shall undertake, direct, and oversee any action necessary and appropriate to carry out its charge; and

RESOLVED FURTHER, that the Special Litigation Committee is vested with the full authority of the Board to take any such action(s), including, without limitation, directing the filing and prosecution of litigation on behalf of the Company, as the Special Litigation Committee in its sole discretion deems to be in the best interests of the Company; and


RESOLVED FURTHER, that the Special Litigation Committee shall exercise the sole and exclusive authority of the Board with respect to the matters delegated to it, and that determinations made by the Special Litigation Committee as to matters within the scope of its charge shall be final and binding on the Company and shall not be subject to review by the Board; and

RESOLVED FURTHER, that the Special Litigation Committee shall have full authority to contact, obtain information from, consult with, and direct the Company's officers and employees, including the Company's General Counsel, in connection with any matters within the Special Litigation Committee's charge; and


RESOLVED FURTHER, that the officers and employees of the Company shall cooperate fully and in all respects with the Special Litigation Committee and its advisors, and that such officers and employees be, and hereby are, authorized, empowered, and directed to respond promptly to the Special Litigation Committee and its advisors and to provide them with any and all information requested by the Special Litigation Committee and its advisors; and

RESOLVED FURTHER, that the Special Litigation Committee is authorized to engage such independent advisors, including its own independent legal counsel, and independent accountant, as the Special Litigation Committee shall deem necessary or desirable in order to carry out its charge; and

RESOLVED FURTHER, that the costs and expenses incurred by the Special Litigation Committee, including costs and expenses of advisors, shall be paid by the Company.



Minutes of a Meeting of the Board of Directors
of Abbott Laboratories
September 16-19, 2024
Page 13



There being no further business, the meeting was then adjourned.

Handwritten signature of Hubert L. Allen.

Hubert L. Allen
Secretary

HLA/anr